Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Xia, Handai; Zhang, Wengang; Zheng, Qiwen; Zhang, Yuqing; Mu, Xin; Wei, Chenxi; Wang, Xiu Wen; Liu, Yanguo

doi:10.1016/j.heliyon.2023.e17400

Cited by 6 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In describing SIPS, we acknowledge the lack of routine collection of CRP in our region and highlight that albumin and NC, but not CRP, are routinely collected in most clinical trials. Albumin forms a central part of other composite biomarker scores, such as the Prognostic Nutritional Index (PNI), Gustave Roussy Immune Score (GRim), Royal Marsden Hospital Prognostic Score (RMH), platelet/albumin ratio (PAR), CRP-albumin-lymphocyte index (CALLY), and NC/albumin ratio (NAR), all of which have demonstrated prognostic significance in patients with NSCLC [69,73,[80][81][82]. Scores incorporating an NLR or derived NLR (dNLR, i.e., NC/(WCC-NC)) backbone have also been developed.…”

Section: Composite Biomarkersmentioning

confidence: 99%

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities

Stares,

Brown,

Abhi

et al. 2024

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a common malignancy and is associated with poor survival outcomes. Biomarkers of systemic inflammation derived from blood tests collected as part of routine clinical care offer prognostic information for patients with NSCLC that may assist clinical decision making. They are an attractive tool, as they are inexpensive, easily measured, and reproducible in a variety of healthcare settings. Despite the wealth of evidence available to support them, these inflammatory biomarkers are not yet routinely used in clinical practice. In this narrative review, the key inflammatory indices reported in the literature and their prognostic significance in NSCLC are described. Key challenges limiting their clinical application are highlighted, including the need to define the optimal biomarker of systemic inflammation, a lack of understanding of the systemic inflammatory landscape of NSCLC as a heterogenous disease, and the lack of clinical relevance in reported outcomes. These challenges may be overcome with standardised recording and reporting of inflammatory biomarkers, clinicopathological factors, and survival outcomes. This will require a collaborative approach, to which this field of research lends itself. This work may be aided by the rise of data-driven research, including the potential to utilise modern electronic patient records and advanced data-analysis techniques.

show abstract

Section: Composite Biomarkersmentioning

confidence: 99%

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities

Stares,

Brown,

Abhi

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…The efficacy of ICIs is dependent on the immune function of the patient, which is influenced by inflammation and nutritional status (21). Numerous studies have shown that certain inflammatory and nutritional biomarkers such as prognostic nutrition index (PNI) and systemic immune-inflammation index (SII) could predict the prognosis of patients with solid tumors who receive ICIs (22)(23)(24)(25). However, to the best of our knowledge, the value of these biomarkers in HCC remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors

Liu,

Zhao,

Zhang

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

The emergence of immune checkpoint inhibitors (ICIs) has provided a new treatment option for patients with hepatocellular carcinoma (HCC). However, further evaluation is needed for determining biomarkers for the use of ICIs. The present study evaluated the prognostic value of certain nutritional and inflammatory markers in patients with HCC who received ICIs. In the present study, the clinical data of 151 patients with HCC who received ICIs at Harbin Medical University Cancer Hospital from January 2019 to December 2021 were collected. The blood parameters of all patients before treatment were collected to evaluate certain nutritional and inflammatory markers, including the prognostic nutrition index (PNI), nutritional risk index (NRI), geriatric NRI (GNRI), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and advanced lung cancer inflammation index (ALI). Patients were grouped using the cut-off value calculated using receiver operating characteristic (ROC) curves, and the relationship between these biomarkers and prognosis was evaluated through survival analysis. Furthermore, the prognostic value of these biomarkers was assessed through multivariate Cox regression analysis and construction of nomograms. Finally, time-ROC curves were plotted to compare the differences in predicting prognosis between the biomarkers. In the preliminary survival analysis, all inflammatory and nutritional markers included in the present study were significantly associated with the prognosis of HCC in patients who received ICIs. Similar results were obtained in a subgroup analysis of patients with different Barcelona Clinic Liver Cancer (BCLC) stages. Multivariate Cox regression analysis demonstrated that GNRI, PNI, BCLC stage and Tumor-Node-Metastasis (TNM) stage were significantly associated with progression-free survival (PFS), whereas GNRI, BCLC stage and TNM stage were also significantly associated with overall survival (OS). Furthermore, the time-ROC curves indicated that nutritional indicators had a higher prognostic value in all indexes, especially GNRI. The C-index (95% confidence interval) of the nomograms for predicting the survival probability of patients who received ICIs were 0.801 (0.746-0.877) and 0.823 (0.761-0.898) for PFS and overall OS, respectively, which also showed high accuracy. In conclusion, the present study demonstrated that PNI, GNRI, NRI, SII, SIRI and ALI were all related to the efficacy of ICIs in HCC and could serve as non-invasive biomarkers for ICI treatment effectiveness. Moreover, compared with inflammatory markers, nutritional markers had greater predictive ability, with GNRI being the biomarker with the best prognostic value.

show abstract

Analysis of therapeutic effects and influencing factors of ICIs in lung-cancer patients

Luo,

Li,

Wang

et al. 2024

Clin Transl Oncol

View full text Add to dashboard Cite

Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cited by 6 publications

References 58 publications

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors

Analysis of therapeutic effects and influencing factors of ICIs in lung-cancer patients

Contact Info

Product

Resources

About